La Jolla Pharmaceutical — Technical Presentation (September 2016)
9 slides from La Jolla Pharmaceutical's technical presentation, Sep 8, 2016
Slide 1: LJPC-401 Phase 1 Results and Development Update
LJPC-401 Phase 1 Results and Development Update September 7, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp
Slide 3: LJPC-401: Overview
LJPC-401: Overview • LJPC-401 is a novel formulation of hepcidin, a naturally occurring regulator of iron absorption and distribution • Primary iron overload Hereditary hemochromatosis (HH) is characterized by a genetic deficiency of hepcidin resulting in excessive iron accumulation – Most common
Slide 4: LJPC-401: Phase 1 Study Design
PRIMARY ENDPOINT Safety and tolerability via review of: Treatment Emergent Adverse Events (TEAEs), changes in clinical lab values, ECGs, vital sign and physical exam data SECONDARY ENDPOINT Serum iron LJPC-401: Phase 1 Study Design • Population: Adult patients at risk of iron overload (e.g., HH, tha
Slide 5: LJPC-401: Phase 1 Results Overview
LJPC-401: Phase 1 Results Overview • Fifteen patients dosed at escalating dose levels from 1 mg to 20 mg Patient subtypes treated: HH = 10; SCD = 3; and thalassemia = 2 • Safety observations No dose-limiting toxicities at any dose level 1 SAE at 1 mg dose level unrelated to study drug – Hospit
Slide 6: LJPC-401: Percent Change in Serum Iron Baseline to Hour 8
Dose Response p=0.008 Individual dose p-values for change from baseline not adjusted for a potential regression to the mean effect. Dose response not adjusted for multiple comparisons. LJPC-401: Percent Change in Serum Iron Baseline to Hour 8 6
Slide 7: LJPC-401: Percent Change in Serum Iron Baseline through Day 7 for 20 mg Dose
Nominal Time from Treatment (hours) Pe rce nt C ha ng e fro m Ba se lin e (% ) 0 8 24 48 168 -100 -75 -50 -25 0 25 Serum Iron: Percent Change from Baseline Change from baseline through day 7: -21% LJPC-401: Percent Change in Serum Iron Baseline through Day 7 for 20 mg Dose 7
Slide 8: LJPC-401: Phase 1 Results Summary
LJPC-401: Phase 1 Results Summary • Fifteen patients received a single dose ranging from 1 mg to 20 mg Patient subtypes treated: HH = 10; SCD = 3; and thalassemia = 2 • Well tolerated with no dose-limiting toxicities Mild to moderate, transient and self-limiting injection-site reactions • Profou
Slide 9: LJPC-401: Update on Registration Plan
• Agreement reached with European Medicines Agency (EMA) on pivotal study design • Randomized, controlled, multi-center study in beta thalassemia patients suffering from iron overload A major unmet medical need in an orphan patient population • Primary endpoint is a clinically relevant measurement
LA Jolla Pharmaceutical — Technical Presentation (September 2016) on 6ix